Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

H Kantarjian, J Cortes, D. W Kim, P Dorlhiac Llacer, R Pasquini, J DiPersio, M. C Muller, J. P Radich, H. J Khoury, N Khoroshko, M. B Bradley Garelik, C Zhu and M. S. Tallman

Blood 113 ( 25 ): 6322 - 6329 , 2009